PEG-modified/site-mutated interleukin-2 SHR-1916 (Jiangsu Hengrui Medicine Co Ltd)

N/A

Report date: 2024/06/05 18:01:27

Base Information

Drug NamePEG-modified/site-mutated interleukin-2 SHR-1916 (Jiangsu Hengrui Medicine Co Ltd)
Drug Alias NameIL-2 derivative SHR-1916PEG-IL-2 (Jiangsu Hengrui Medicine Co Ltd)SHR-1916
ClassificationBiologics > Protein drugs > Non-recombinant cytokines
Mechanisms of ActionInterleukin-2 replacements
TargetsInterleukin-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiangsu Hengrui Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A